MTORC1 inhibition by sirolimus as adjunctive treatment in experimental pneumococcal meningitis.

ABSTRACT: Sirolimus, an inhibitor of mammalian target of rapamycin complex (mTORC) 1, a regulatory protein involved in seizures and a modulator of inflammation, represents a potential new treatment strategy for pneumococcal meningitis. This study investigates the effects of mTORC1 inhibition using sirolimus in a mouse model of experimental pneumococcal meningitis. In a prospective, investigator-blinded and randomized trial, 96 mice were infected intracisternally with Streptococcus pneumoniae serotype 2. Mice were randomized for treatment with sirolimus and all mice received antibiotic treatment. In a clinical severity experiment, 48 mice were infected and scored every 4 h for disease severity until 72 h. In a time-point experiment, 48 mice were infected and terminated at 6 or 24 h after infec

SUBMITTER: Koning R 

PROVIDER: S-EPMC12784197 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature